These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20953941)

  • 1. Detecting CD20-rituximab specific interactions on lymphoma cells using atomic force microscopy.
    Li M; Liu L; Xi N; Wang Y; Dong Z; Li G; Xiao X; Zhang W
    Sci China Life Sci; 2010 Oct; 53(10):1189-95. PubMed ID: 20953941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.
    Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
    J Mol Recognit; 2013 Sep; 26(9):432-8. PubMed ID: 23836471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients.
    Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
    Exp Cell Res; 2013 Nov; 319(18):2812-21. PubMed ID: 23896027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells.
    Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
    Cell Immunol; 2014 Aug; 290(2):233-44. PubMed ID: 25117605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab.
    Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
    J Microsc; 2014 Apr; 254(1):19-30. PubMed ID: 24499016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy.
    Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
    Scanning; 2013; 35(1):40-6. PubMed ID: 22890585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
    Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Distribution and force spectroscopy of CD20 antigen-antibody binding on the B cell surface].
    Wang Q; Lu Y; Li S; Wang M; Cai J
    Sheng Wu Gong Cheng Xue Bao; 2011 Jan; 27(1):131-6. PubMed ID: 21553499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy.
    Li M; Xiao X; Liu L; Xi N; Wang Y
    J Immunol Methods; 2016 Sep; 436():41-9. PubMed ID: 27374866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells.
    Semac I; Palomba C; Kulangara K; Klages N; van Echten-Deckert G; Borisch B; Hoessli DC
    Cancer Res; 2003 Jan; 63(2):534-40. PubMed ID: 12543813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K; Yamazaki T; Sawada U; Ishizuka H; Aizawa S
    Leuk Res; 2006 May; 30(5):625-31. PubMed ID: 16289746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
    Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
    Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K; Terui Y
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.